{"entity":{"id":"nct05429632","kind":"trial","name":"Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT","aka":[],"tldr":"A phase 3 trial of mocravimod in acute myeloid leukaemia, run by Priothera SAS, now recruiting.","summary":"Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT is a phase 3 interventional study registered as NCT05429632 by Priothera SAS, with 366 participants planned, started 2022-06-16 and due to reach its primary completion in 2027-05. Interventions recorded: mocravimod.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05429632","url":"https://clinicaltrials.gov/study/NCT05429632"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05429632","phase":"3","setting":"Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT","sponsor":"Priothera SAS","enrolled":366,"outcomes":[]},"route":"/trials/nct05429632/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}]}}